New Two-Pronged attack on advanced cancers shows promise in early trial
NCT ID NCT04317105
Summary
This early-stage trial is testing a new combination of three drugs for patients with advanced solid tumors that have spread and have specific genetic changes (PIK3CA or PTEN). The goal is to see if adding a drug called copanlisib to standard immunotherapy drugs (nivolumab and ipilimumab) is safe and works better than immunotherapy alone. The study will enroll about 54 adults to find the best dose and see how well the combination controls the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
University of Texas Medical Branch
Galveston, Texas, 77555-0565, United States
-
University of Texas at Austin
Austin, Texas, 78712, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.